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Context: Bardet-Biedl syndrome (BBS) is a rare autosomal recessive disorder in which previous 
reports have described obesity and a metabolic syndrome. 
Objective: Describe the endocrine and metabolic characteristics of a large BBS population 
compared with matched controls. 
Design: Case-control 
Setting: Hospital clinic 
Patients: A clinical/genetic diagnosis of BBS 
Intervention: None 
Main outcome measure: Prevalence of metabolic syndrome 
Results: One hundred and fifty-two subjects were studied. Eight-four (55.3%) were male and 
mean (±SD) age was 33.2±1.0 years. Compared with age, gender and BMI matched controls, 
fasting glucose and insulin levels were significantly higher in BBS subjects (glucose: BBS: 
5.2±1.2mmol/l vs control 4.9±0.9mmol/l, p=0.04; insulin: BBS: 24.2±17.0pmol/l vs control 
14.2±14.8pmol/l, p<0.001). Serum triglycerides were significantly higher in BBS subjects 
(2.0±1.2mmol/l) compared with controls (1.3± 0.8mmol/l p<0.001) but total 
cholesterol/HDL/LDL were similar in both groups. Systolic blood pressure was higher in the 
BBS group (BBS 135±18 mmHg vs controls 129±16mmHg (p=0.02). Alanine transaminase 
(ALT) was raised in 34 (26.8%) BBS subjects, compared to 5 (8.9%) controls (p=0.01). The 
presence of a metabolic syndrome, using IDF criteria, was significantly higher in the BBS group 
(54.3%) compared to controls (26% p<0.001). Twenty-six (19.5%) of BBS males were 
hypogonadal (serum testosterone 9.9±5.3 mmol/l) but significant pituitary abnormalities were 
uncommon. Subclinical hypothyroidism was present in 24/125 (19.4%) patients with BBS 
compared with 3/65 (4.6%) controls (p=0.01).  
Conclusions: Insulin resistance and the metabolic syndrome are increased in adult BBS 
compared with matched controls. Increased subclinical hypothyroidism in the BBS cohort is a 
novel finding that needs further investigation. 
A large case control study examined endocrine and metabolic characteristics in adult Bardet-Biedl 

























































Bardet Biedl syndrome (BBS) is a rare autosomal recessive disorder characterised by a 
pleiotropic phenotype including obesity, rod cone dystrophy, polydactyly, hypogonadism, renal 
abnormalities and cognitive impairment (1).  
The prevalence of BBS is estimated to be 1 in 125,000-160,000 in Europe which is 
equivalent to around 400 cases in the UK (2,3). It is more prevalent in some other countries, 
attributed to higher levels of consanguinity, with an estimated prevalence in an Arab population 
of 1 in 13,500 as an example (4). There is a high prevalence of BBS in Newfoundland (1 in 
18,000), which is thought to be due to the geographical and cultural isolation of this community, 
high levels of kinship and founder effects (5,6).  
The diagnosis of BBS is clinical and at least 4 of the primary features (polydactyly, obesity, 
learning disabilities, hypogonadism in males, renal anomalies) or 3 primary features and 2 
secondary features must be present. Secondary features include type 2 diabetes mellitus (T2DM), 
polyuria, polydipsia from nephrogenic diabetes insipidus, hepatic fibrosis, ataxia/poor 
coordination, mild spasticity, speech disorder/delay, dental crowding/hypodontia/small 
roots/high arched palate, left ventricular hypertrophy/congenital heart disease (7). The diagnosis 
can be confirmed with direct genetic sequencing in 80% of patients (8).To date, 22 BBS genes 
on multiple loci have been discovered (9–12), with the most common gene mutations, BBS1 and 
BBS10, accounting for 23.2% and 20% of cases respectively (1,6). BBS is part of the family of 
‘ciliopathies’ as these genes encode proteins involved in the function and maintenance of 
primary cilia (13–15).  
Obesity is an important cause of morbidity in BBS but the aetiology is unclear.   One study 
from a primarily pediatric cohort (16) found hyperleptinaemia and increased intra-abdominal fat 
in BBS compared to controls. A predisposition to central obesity may be associated with 
increased metabolic syndrome but there are currently few data in adults, with at least one study 
finding normal fasting insulin resistance (16). Another  study reported that 20 patients with BBS 
had a similar basal metabolic rate and energy intake when compared with body mass index 
(BMI)-matched controls, but the physical activity level of the patients with BBS was lower (17). 
Further research into other endocrine features of BBS found a high frequency of pituitary 
abnormalities on MRI in 11 children with BBS (18) but again there are no comparable adult data. 
We aimed to provide the first detailed case-controlled description of the endocrine and 
metabolic characteristics from a large BBS adult clinic population.  
METHODS 
Subjects 
Patients with BBS were identified through the BBS Multi-disciplinary Team clinics at Guy’s & 
St Thomas’ Hospitals NHS Foundation Trust (GSTT) and University Hospitals Birmingham 
NHS Foundation Trust (UHB), UK, the two main specialist clinics in England for adults with 
BBS. The BBS diagnosis was made on clinical grounds using established criteria (7) and 
samples for genetic analysis were taken where possible. Each patient attending the BBS clinic is 
assessed by an endocrinologist, nephrologist, clinical geneticist, ophthalmologist and dietician. 
Control subjects were identified from an obesity clinic at GSTT (n=32, 31% of total) and 
from participants in other research studies undertaken by King’s Diabetes Research group, 
King’s College London, involving neuro-imaging and appetite (n=71). The research studies 
excluded CKD stages 3-5, so formal comparison analyses for CKD between BBS and controls 
were not performed but the distribution of CKD is described in the results for information. All 
























































Research Ethics Committee. Informed consent was collected from control participants. Data 
collected from BBS patients were part of routine clinical care and specific informed consent was 
not required. Controls were matched with BBS subjects by age, sex and BMI using frequency 
matching. The case control comparison was not ethnicity specific. 
Clinical and laboratory assessment 
Blood samples were taken after a 9 hour fast. Morning medications were omitted until after the 
sample. Full blood count, renal and liver function tests, thyroid function tests, lipid profile, 
glucose and insulin were all measured in the fasted state. Serum insulin was measured using a 
chemiluminometric sandwich immunoassay (Advia Centaur, Siemens). Anthropometric 
measurements were taken with participants wearing light clothing. Waist circumference was 
measured at the level of the iliac crest in expiration. Body mass index (BMI) was calculated as 
kilogram per square metre. Obesity was defined as BMI>30kg/m2. Blood pressure was taken 
once in the seated position. 
The International Diabetes Federation (IDF) criteria were used to identify metabolic 
syndrome. This defines metabolic syndrome as central obesity (measured by ethnicity specific 
values for waist circumference) and any two of the following: raised triglycerides (>1.7mmol/l), 
reduced HDL cholesterol (<1.03mmol/l in males, <1.29mmol/l in females), raised blood pressure 
(systolic>130mmHg or diastolic>85mmHg) and raised plasma fasting glucose (>5.6mmol/l) or if 
the patients are already on treatment for any of these factors (19). Levels of liver transaminases 
above the local laboratory reference range were used as an indication for biochemical evidence 
of NAFLD, if no other diagnosis was clinically apparent. Subclinical hypothyroidism was 
identified if thyroid stimulating hormone (TSH) levels were raised but serum free thyroxine (T4) 
levels were within the normal laboratory reference range.  
Presence of hypogonadism in our BBS group was defined by characteristic clinical signs and 
symptoms accompanied by low total testosterone and abnormal luteinizing hormone 
(LH)/follicle stimulating hormone (FSH). Sex hormone binding globulin (SHBG) and free 
testosterone were measured.   
For a sub-group of subjects (n=85) the endocrine and metabolic characteristics for the four 
most common mutations were described. Unadjusted comparisons were only made between 
BBS1 and BBS 10 mutations due to the small numbers in each group. 
Statistical Analysis 
Data were analysed using the IBM SPSS Statistics (Version 19.0 for Windows, Armonk, NY: 
IBM Corp). Student’s t-test was used for continuous variables which showed a normal 
distribution and the Mann-Whitney U test was used for continuous variables that did not show a 
normal distribution after log transformation. A Data that were normally distributed are presented 
as mean ± standard deviation (SD). Chi squared test was used for frequencies. Two-tailed p-
values were considered significant at <0.05. 
RESULTS 
Demographics & Clinical characteristics 
One hundred and fifty-two subjects with BBS were included. Eighty-four (55.3%) were male. 
Mean age was 33.2±11.8 years (range 16-58 years) and BMI 35.7±7.8 kg/m2 (range 19.2-57). 
Figure 1 shows the BBS subjects categorised by BMI. Overall, 102 (76.3%) BBS subjects were 
obese (74.1% of females and 78.1% of males). One patient had a previous gastric band but 
otherwise no BBS patients took weight loss medication. One hundred and twenty-six (82.9%) 
























































BBS1 mutation [71 subjects (46.7%)], with 17 subjects (11.1%) carrying the BBS2 mutation and 
20 subjects (14.4%) carrying the BBS10 mutation (Table 1). 
Controls consisted of 103 individuals who were matched for age, sex and BMI with 48 
(46.6%) males, a mean age of 32.5±8.0 years (range 16-52 years) and a mean BMI of 
34.2±9.1kg/m2 (range 20.1-54.8). Sixty-two (60.1%) controls were white Caucasian (Table 2). 
Clinical and biochemical characteristics were compared between BBS subjects and matched 
controls (Table 3). Fasting glucose (BBS 5.2±1.2 vs control 4.9±0.9 mmol/l, p=0.04) insulin 
(24.2±17.0 vs 14.2±14.8 pmol/l, p<0.001) and HOMA IR (5.55±4.14 vs 3.09±4.53, p=0.003) 
were significantly higher in the BBS group compared with the non-BBS group. These were 
unadjusted comparisons.   Glycated haemoglobin was not different between the 2 groups, 
although the BBS group had mean HbA1c that was within the range for impaired glucose 
tolerance. Subjects with known diabetes (n=25) were excluded from glucose/insulin/HOMA-
IR/HbA1c analyses, but were included in all other analyses. 
There was no difference in total cholesterol, high density lipoprotein (HDL) cholesterol or 
low density lipoprotein (LDL) cholesterol between the two groups. However, serum triglycerides 
were significantly higher in the BBS group (2.0±1.2mmol/l) compared with controls (1.3± 
0.8mmol/l p<0.001). Systolic blood pressure was higher in the BBS group (BBS 135.2±18.3 
mmHg vs controls 129.0±16.1 mmHg (p=0.02). Nine BBS patients were taking anti-
hypertensive medication compared with none in the control group. Alanine transaminase (ALT) 
was raised above the reference range in 34 (26.8%) individuals with BBS, compared to five 
(8.9%) controls (p=0.01). The presence of a metabolic syndrome, using IDF criteria, was 
significantly higher in the BBS group (54.3%) compared to controls (26% p<0.001). The 
individual features of the metabolic syndrome are also shown in table 3. BBS subject had 
significantly increased frequency of all features of the metabolic syndrome except for HDL 
cholesterol (table 3). 
Polycystic ovary syndrome was present in 10/68 (14.7%) female BBS subjects. Two BBS 
females were known to have given birth to healthy infants, and four males from our BBS cohort 
have fathered children. Twenty-six (19.5%) males were hypogonadal (primary in four patients 
and secondary in 22 patients (one secondary to raised prolactin as described below, with 
normal/low gonadotrophins in others). Sex hormone binding globulin (SHBG) was low in 96.1% 
(25/26) of the clinically hypogonadal patients.  All patients were assessed thoroughly clinically 
and biochemically for diabetes insipidus, and two (0.01%) patients were confirmed to have an 
established diagnosis of nephrogenic diabetes insipidus. 
Twenty-four (15.8%) BBS patients had T2DM and 1 patient had type 1 diabetes. Of those 
with T2DM, 13 were male and 11 were female with a mean age of 40.4±9.6 years. Management 
of T2DM was as follows: 6 patients were diet controlled, 8 were taking metformin and 10 used 
insulin to manage their diabetes. The mean HbA1c of those with T2DM was 62±28 mmol/mol 
(7.8±4.8%). 
One hundred and two BBS patients (78.4%) had normal pituitary function. Of the remaining 
patients, 15 (11.5%) had an isolated low IGF-1, 5 had mild hyperprolactinaemia (prolactin <1000 
mIU/l) and 7 had isolated low prolactin.  One patient had significant hyperprolactinemia 
(prolactin of 6391IU/ml (102-496IU/ml) with suppressed gonadotrophins and total testosterone 
of 3.5 nmol/l.  A subsequent MRI showed pituitary hypoplasia. 
Most BBS subjects were euthyroid (77.0%), ten (6.5%) had hypothyroidism and one had 
hyperthyroidism. There were 24/125 (19.4%) BBS patients with subclinical hypothyroidism 
























































Four (3.9%) patients had stage 5 CKD, 4 (3.9%) stage 4 CKD and 14 (13.7%) stage 3 CKD.  
An additional four patients had functioning renal transplants (Figure 2).  In the control cohort, no 
patients had Stage 5 or 4 CKD, 1 (1.2%) Stage 3 CKD, 31 (38.3%) Stage 2 CKD and 49 (60.5%) 
Stage 1 CKD.   
The main endocrine and metabolic features of the most common mutations are shown in 
table 4. Unadjusted comparisons were only performed between BBS1 and BBS10 mutations due 
to small numbers in the sub-groups. Compared with BBS1 subjects, BBS10 mutation was 
associated with a trend towards increased diastolic blood pressure (BBS1 81.4±9.4 v BBS10 
89.1±8.4 mmHg p=0.05), increased HOMA-IR (BBS1 5.8±4.3 v BBS10 12.4±4 p=0.02) and 
increased triglycerides (BBS1 1.71±0.8 v BBS10 2.7±1.5 mmol/l p=0.03) despite a younger age 
in our study group (BBS1 35±11.2 v 27.7±11.3 years p=0.02). BBS10 subjects also had a higher 
prevalence of hypogonadism (BBS1 6 (10.5%) v BBS10 6 (42%) p=0.01).  
DISCUSSION 
To our knowledge, this is the most detailed endocrine and metabolic characterisation undertaken 
to date of a large adult BBS population. Our data also provide the first robust confirmation that 
the metabolic syndrome is more prevalent in BBS compared to matched controls and is in 
keeping with increased cardiovascular mortality. Specifically, fasting blood glucose, 
triglycerides and systolic blood pressure were raised in the BBS group, and overall insulin 
resistance was higher. Contrary to previous reports, global pituitary dysfunction is uncommon, 
but there is an increased prevalence of male hypogonadism. We also report novel data showing 
increased subclinical hypothyroidism in BBS. 
Data from a cohort study that followed 46 BBS subjects over a prolonged time period 
showed that 48% developed T2DM at a mean age of 43 years (5). Cardiovascular mortality was 
also increased, with median survival of 63 years. Increased prevalence of metabolic syndrome 
has been suggested in case series and cross-sectional data, describing the metabolic syndrome or 
its components, in adult BBS subjects (20,21). However, these were small studies (three cases in 
one study) and they also had discrepant findings. One study showed that in 33 BBS patients with 
an average age of 26.3 years, hypertension and dyslipidaemia were common, with six per cent 
having overt diabetes.  
Case-control data in a predominantly pediatric population have shown that at a mean age of 
14 years, BBS subjects had increased visceral adiposity, raised diastolic blood pressure and 
hypertriglyceridemia (16). Our study shows higher triglycerides, systolic blood pressure and 
fasting blood glucose in adult BBS subjects, despite anti-hypertensive medication in a small 
number. Raised systolic blood pressure in the BBS group is a novel finding. This may be related 
to insulin resistance but it is also possible that BBS proteins are associated with blood pressure 
control. Rodent data have implicated BBS genes in the regulation of vascular function (22). 
Subjects had marked fasting hyperinsulinemia compared to matched controls. In the case 
control study by Feuillan et al. BBS subjects showed a trend towards higher fasting insulin but 
this did not reach statistical significance, with fasting glucose similar in both groups. These are 
important data taken together, suggesting that hyperinsulinemia starts at an early age in BBS and 
by a subject’s third decade, hyperinsulinemia is more pronounced and fasting glucose is raised, 
although still within the non-diabetic range.  Insulin resistance is the common feature that links 
the different components of the metabolic syndrome, and this appears to increase steadily 
throughout adulthood in BBS subjects until, as suggested by the cohort study above, they may 
























































matching of our study, together with findings from Feuillan et al., suggest that progression of 
hyperinsulinemia to T2DM is above and beyond what would be expected from obesity alone.  
The reasons for this are not clear. It is known that adipose tissue partitioning is abnormal in 
BBS from an early age, and the predisposition to visceral adiposity may lead to increased 
features of metabolic syndrome as an adult. This subsequently increases the prevalence of T2DM 
and cardiovascular mortality. BBS subjects are known to have hyperleptinemia and are likely to 
have leptin resistance (23). This may be mediated by impaired leptin receptor trafficking and 
signalling, resulting from altered or deficient BBS proteins (24). Leptin has an overall effect of 
decreasing bodyweight, and db/db (leptin-receptor) deficient mice have increased subcutaneous 
and visceral adipose compartments (25).  Predisposition to increased visceral adipose tissue is 
also likely to be genetically determined, as is found in certain ethnic groups, although exact 
mechanisms have yet to be elucidated. 
Alternative mechanisms for insulin resistance in BBS may be related to the requirement of 
BBS proteins to regulate the trafficking of insulin receptors. Recent data, using knockout mouse 
models, have shown that beta cell ciliary dysfunction is associated with disruption in insulin 
secretion/signalling and that the BBS protein/insulin receptor interaction has consequences on 
whole body insulin action and glucose metabolism (26,27). Intriguingly, not all BBS mutations 
may cause insulin resistance, with data suggesting BBS12 mutations associated with improved 
insulin sensitivity and glucose utilization (28).  
The prevalence of overt diabetes in our study with mean age of 33 years was around 15%, 
compared to 6% in a younger population (mean age 26.3 years) (21) and 48% in BBS subjects a 
decade older (5). Diabetes was managed with diet or metformin in many cases. The approximate 
tripling of the incidence of diabetes in a decade from the early 30’s is useful clinical information, 
and may represent an opportunity to prevent the onset of T2DM with lifestyle modification. 
Another small study in pediatric patients of Turkish origin found a high incidence of pituitary 
hormone abnormalities (18).  It reported evidence of hyperprolactinaemia, primary and 
secondary hypogonadism, one case of precocious puberty and one case of growth hormone 
deficiency requiring treatment. MRI pituitary scans were performed in all subjects, and showed 
abnormalities in 63% including pituitary hypoplasia, Rathke’s cyst and one enlarged pituitary 
gland. A further two case reports have described full dynamic endocrinological evaluations in 
single adults BBS patients, with both showing secondary hypogonadism but no other specific 
abnormalities (29,30). Our data do not suggest widespread pituitary hormone abnormalities in 
adult BBS subjects. Significant hyperprolactinaemia was only found in one subject in whom 
MRI showed pituitary hypoplasia. MRI scans were not performed in the remainder of our 
subjects, so it is not possible to confirm or refute the findings in the above paediatric study.  
Hypogonadism however was common, and this is in keeping with previous reports (7). The 
aetiology was secondary hypogonadism in the majority of cases, most of which had been 
relatively asymptomatic and unrecognised before attending the specialised clinic. Most male 
subjects also had accompanying microgenitalia. The mechanism for secondary hypogonadism is 
unknown but gonadotrophin deficiency and obesity related hypogonadism are likely to be 
contributory factors. Our clinical practice has been not to replace asymptomatic BBS men with 
testosterone. Future studies will be useful in determining whether testosterone replacement in 
BBS men with secondary hypogonadism will improve metabolic parameters including body 
























































Diabetes insipidus is considered an established feature of BBS.  Our results suggest that 
significant DI in adults is a rare occurrence and when present, it is likely to reflect a lack of renal 
responsiveness to DDAVP due to nephrogenic rather than cranial DI.  
The increased prevalence of subclinical hypothyroidism was an unexpected finding. To our 
knowledge, this has not been previously described. Outside BBS, subclinical hypothyroidism is 
the pre-cursor to overt hypothyroidism in most cases, is primary in aetiology and usually related 
to autoimmune thyroid disease. Further work will need to be done to assess whether thyroid 
autoimmunity is increased in BBS. Our data suggest that it is useful to check thyroid function 
periodically in people with BBS. If abnormal results are found, our usual practice would be to 
assess symptomology, ascertain the presence or otherwise of thyroid autoimmunity and then 
consider monitoring or a trial of treatment with levothyroxine. Subclinical hypothyroidism has 
been associated with increased prevalence of the metabolic syndrome and central obesity, 
although the data are heterogeneous and sometimes conflicting (31,32).   
The prevalence of chronic kidney disease (CKD) was similar to previous cohorts, although it 
is of interest that stage 1 and 2 CKD were not different from obese controls. Nephrogenic 
diabetes insipidus is not a widely recognised feature of BBS, and there were only 2 cases in our 
cohort and both were diagnosed in childhood. Our subjects were all thoroughly evaluated by an 
endocrinologist and a nephrologist, and we feel that this is likely to be an accurate prevalence. 
With regards to the gene mutations in Bardet Biedl syndrome, the majority of patients 
(61.1%) fell in the BBS1 or BBS10 categories, closely followed by mutations in BBS2. This order 
of the number of cases of BBS attributable to each mutation is reflected in previous studies (1). 
There was a high prevalence of BBS1 M390R mutations (80%) within the BBS1 cohort, which 
reflects the high frequency of Caucasians in our study population. Previous studies have 
confirmed that within a multi-ethnic cohort, a number of novel gene mutations are observed and 
the spectrum of clinical characteristics can overlap with those of other ciliopathies, namely 
Alstrom and McKusick-Kauffman syndromes (33). 
Further data from our group have shown that those with missense mutations in the BBS1 
gene have lower cardiovascular risk markers (hypertension, hyperlipidaemia, impaired glucose 
tolerance) than BBS10 or other BBS1 mutations (34). 
We performed a limited unadjusted sub-study analysis between the two most common 
mutations BBS1 and BBS10, and found that insulin resistance and features of the metabolic 
syndrome were increased in the BBS10 group, despite a younger age. Although numbers in the 
groups were small, our data suggest that hypogonadism was also increased in the BBS10 group, 
despite similar BMI, which may be a contributing factor in the increased metabolic disruption 
seen in this group. These data are also in keeping with data from Feuillan et al. suggesting lower 
HOMA-IR, serum leptin, BMI and abdominal fat in BBS1 compared with BBS10 mutations 
(16). We acknowledge that differences in clinical manifestation/ severity may occur with 
different BBS mutations and longer term prospective studies, allowing for the effect of 
interventions and medication may provide further understanding of the mechanisms of 
development of endocrine and metabolic adverse features.   Recognition of the prevalence of 
these complications will inform the development of clinical interventions (eg weight 
management, thyroid hormone use) that may be of value in managing the patient with BBS. 
Our study has some limitations. We did not collect detailed information with regards to 
dietary intake and hence were not able to adjust for this in our analyses. Data for fasting samples 
were collected within the setting of routine clinic care, and although patients were given standard 
























































measurements for BBS participants were also taken as part of routine clinical care, and hence 
were not measured on multiple occasions. Body mass index alone as a measure of obesity has 
limitations and future work to compare other parameters such as serum leptin, would be 
informative. 
To conclude, our study reports increased prevalence of insulin resistance and the metabolic 
syndrome in adult BBS subjects compared to matched controls. Overt diabetes had not yet 
developed in many subjects and this may represent an opportunity to intervene with lifestyle 
measures. Subclinical hypothyroidism was a novel finding that will need further exploration. 
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Figure 1 Bardet-Biedl (BBS) subjects stratified according to gender and body mass index (BMI) 
Figure 2 Bardet-Biedl syndrome (BBS) patients and controls stratified according to chronic 
kidney disease stage 
Table 1 Gene mutations in BBS group 
Gene mutation n (%) 
BBS1 71 (46.7%) 
BBS2 17 (11.1%) 
BBS8 1 (<1%) 
BBS9 1 (<1%) 
BBS10 20 (13.1%) 
BBS12 8 (<1%) 
BBS6MKKS* 2 (<1%) 
























































BBS2 BBS5 1 (<1%) 
Not known** 30 (19.7%) 
*MKKS: McKusick-Kaufman Syndrome 
** None of the current known gene mutations found  
Table 2 Demographic details of BBS and control subjects 
 BBS Mean ± SD Control Mean ± SD p value 
Age (years) 33.2±11.8 32.5±7.8 0.75 
BMI (kg/m2) 35.7±8.0 34.2±9.1 0.13 
Sex (% male) 55.3% (84) 46.6% (48) 0.17 
Table 3 Clinical Features of Bardet-Biedl (BBS) subjects compared to age, sex and body mass 
index (BMI) matched controls. 
Variable BBS subjects (n) Mean ± SD Control subjects (n) Mean ± SD p value 
Fasting glucose (mmol/L) 5.2 ±1.2 (109) 4.9±0.9 (98)  0.04 
Fasting insulin (pmol/L) 24.2±17.0 (46) 14.2±14.8 (78) <0.001 
HOMA-IR 5.55±4.14 (46) 3.09±4.53 (78) 0.003 
HbA1c (mmol/mol (%)) 42±15 (6.0±1.4) (101) 40±10 (5.8±0.9) (60) 0.37 
Cholesterol (mmol/L) 4.9±1.0 (129) 4.8±0.9 (88) 0.78 
HDL Cholesterol (mmol/L) 1.2±0.3 (126) 1.2±0.4 (87) 0.47 
LDL Cholesterol (mmol/L) 2.8±0.9 (84) 2.9±0.9 (87) 0.21 
Triglycerides (mmol/L) 2.0±1.2 (130) 1.3±0.8 (88) <0.001 
Systolic BP (mmHg) 135.2±18.3 (100) 129.0±16.1 (67) 0.02 
Diastolic BP (mmHg) 81.4±11.4 (100) 80.3±11.6 (70) 0.55 
Prevalence of metabolic 
syndrome 
54.3% (63/116) 26% (26/100) <0.001 
Prevalence of subclinical 
hypothyroidism 
19.4% (24/124) 4.6% (3/65) 0.01 
Prevalence of hypogonadism 19.5% (26/133) not available Not available 
Primary 15.4%(4/26) 
Secondary 84.6% (22/26) 
Raised alanine transaminase 
(ALT) 
26.8% (34/127) 8.9% (5/56) 0.01 
Metabolic Syndrome parameters 
Central obesity 77%(101/131)  60% (62/103) 0.006 
Raised triglycerides 
(>1.7mmol/L) 
55% (71/130) 21% (18/88) <0.0001 
Reduced HDL cholesterol 
(<1.03mmol/L in males, 
<1.29mmol/L in females) 
 40% (51/126) 45% (39/87) 0.53 
Hypertension 
(systolic>135mmHg or diastolic 
>85mmHg) 
 67% (67/100) 43% (30/70) 0.002 
Raised fasting plasma glucose 
(>5.6mmol/L) 
26% (28/109) 8% (8/98) 0.0008 
Table 4 Comparison of common genotypes and their endocrine and metabolic characteristics 
 BBS1 n=57 BBS2 n=10 BBS10 n=14 BBS12 n=4 p value* 
Male n (%) 31 (54) 6 (60) 11 (79) 3 (75) 0.1 
Age (years) 35±11.2 36.6±12.3 27.2±11.3 30±12.3 0.02 
BMI (kg/m2) 34.2±7.1 41.5±9.8 36.9±8.7 35.8±6.8 0.31 
Systolic BP 
(mmHg) 
135.1±13.3 139.3±18.7 145.4±24.9 137.7±17.5 0.27 
Diastolic BP 
(mmHg) 
81.4±9.4 87.2±9.6 89.1±8.4 78.7±7.6 0.05 
HOMA-IR 5.8±4.3 7.1±1 12.4±4.0 4.4±1 0.02 
Triglycerides 
(mmol/l) 
1.7±0.8 2.6±1.2 2.7±1.5 2.7±1.8 0.03 
Metabolic 
syndrome present n 





























































9 (15.7) 3 (30%) 4 (28%) 2 (50%) 0.3 
Hypogonadism n 
(%) 
6 (10.5) 2 (20) 6 (42) 0 0.01 
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